IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1051-1075 out of 1331.

<< < 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 > >>

Public Release: 13-Jan-2015
Journal of Community and Supportive Oncology
Clinical trial shows benefits of animal-assisted therapy in adult cancer patients undergoing complex cancer treatment with chemotherapy and radiation therapy
Therapy dogs may improve the emotional well-being of some cancer patients, according to results of a clinical study, the first to document the benefits of animal-assisted therapy in adult cancer patients. The research was made available this week in the Journal of Community and Supportive Oncology.
Good Dog Foundation, Pfeizer

Contact: Lucia Lee
lucia.lee@mountsinai.org
917-837-8914
The Mount Sinai Hospital / Mount Sinai School of Medicine

Public Release: 13-Jan-2015
PeerJ
Can inhaled oxygen cause cancer?
The ancient physician/alchemist, Paracelsus, said: 'The dose makes the poison.' According to a new study published in PeerJ, even oxygen may fall prey to the above adage. While essential to human life, aspects of oxygen metabolism may promote cancer. Capitalizing on the inverse relationship of oxygen concentration with elevation, researchers found lower rates of lung cancer at higher elevations, a trend that did not extend to non-respiratory cancers, suggesting that carcinogen exposure occurs via inhalation.

Contact: Kamen Simeonov
kamen.simeonov@gmail.com
304-685-3206
PeerJ

Public Release: 13-Jan-2015
Lancet Haematology
New test helps guide treatment for bone marrow transplant patients with graft vs. host disease
Innovative scoring system uses 'Ann Arbor raft versus host disease score' to better predict how patients will respond, minimize side effects
NIH/National Cancer Institute, NIH/National Heart, Lung, and Blood Institute, NIH/National Institute of Allergy and Infectious Diseases, Doris Duke Charitable Fund, American Cancer Society, Judith Devries Fund

Contact: Mary Masson
mfmasson@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 13-Jan-2015
Cancer Research
New target identified for potential brain cancer therapies
Researchers from Virginia Commonwealth University Massey Cancer Center and the VCU Institute for Molecular Medicine have identified a new protein-protein interaction that could serve as a target for future therapies for the most common form of brain cancer, glioblastoma multiforme.
National Institutes of Health, National Foundation for Cancer Researcher, James S. McDonnell Foundation, VCU Massey Cancer Center

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University

Public Release: 13-Jan-2015
JAMA
Breast cancer diagnoses, survival varies by race, ethnicity
Among nearly 375,000 US women diagnosed with invasive breast cancer, the likelihood of diagnosis at an early stage, and survival after stage I diagnosis, varied by race and ethnicity, with much of the difference accounted for by biological differences, according to a study in the Jan. 13 issue of JAMA.

Contact: Julie Saccone
julie.saccone@wchospital.ca
416-323-6400
The JAMA Network Journals

Public Release: 13-Jan-2015
Journal of Interferon & Cytokine Research
Do cytokines have a role in the initiation and progression of breast cancer?
Emerging data on the role of inflammation and the immune system in the development, growth, and spread of breast tumors have focused increased attention on the role cytokines such as interleukin and transforming growth factor-β play in breast cancer initiation, protection, and metastasis. A comprehensive overview of this new knowledge and its potential to lead to novel therapeutic approaches is presented in a Review article in Journal of Interferon & Cytokine Research.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 13-Jan-2015
Journal of American College of Surgeons
UCLA researchers develop new tool to predict postoperative liver cancer recurrence after transplant
University of California Los Angeles transplantation researchers have developed a novel method that more accurately calculates the risk of disease recurrence in liver cancer patients who have undergone a liver transplant, providing a new tool to help physicians make treatment and surveillance decisions.

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-794-2262
University of California - Los Angeles Health Sciences

Public Release: 13-Jan-2015
Clinical Cancer Research
Tumor micro-environment is a rough neighborhood for nanoparticle cancer drugs
Nanoparticle drugs -- tiny containers packed with medicine and with the potential to be shipped straight to tumors -- were thought to be a possible silver bullet against cancer. However new cancer drugs based on nanoparticles have not improved overall survival rates for cancer patients very much. Scientists at the University of North Carolina at Chapel Hill now think that failure may have less to do with the drugs and tumors than it does the tumor's immediate surroundings.

Contact: Thania Benios
thania_benios@unc.edu
919-962-8596
University of North Carolina at Chapel Hill

Public Release: 12-Jan-2015
Blood
'Survival' protein a target in drug-resistant non-Hodgkin lymphomas
Melbourne researchers have discovered that targeting a cell 'survival' protein could help treat some lymphomas, including those cancers with genetic defects that make them resistant to many existing therapies.
Australian National Health and Medical Research Council, Cancer Therapeutics Cooperative Research Centre, Cancer Council Victoria, The Lady Tata Memorial Trust, Leukemia & Lymphoma Society, Victorian Government

Contact: Alan Gill
gill.a@wehi.edu.au
61-393-452-719
Walter and Eliza Hall Institute

Public Release: 12-Jan-2015
Lancet Oncology
FDA approved drug extends survival for patients with rare cancer
Sunitinib, an agent approved for use in several cancers, provides unprecedented antitumor activity in thymic carcinoma, a rare but aggressive tumor of the thymus gland, according to a phase II clinical trial.
National Institutes of Health, NIH/National Cancer Institute, Cancer Therapy Evaluation Program

Contact: Karen Teber
km463@georgetown.edu
Georgetown University Medical Center

Public Release: 12-Jan-2015
Molecular Cancer Research
Potentially targetable signaling pathway generates slowly proliferating, chemo-resistant cancer cells
A signaling pathway responsible for the generation of slowly proliferating cancer cells, which are hard to eradicate with current treatments and thought to be a cause of subsequent disease relapse, has been reported in a Rapid Impact study published in Molecular Cancer Research, a journal of the American Association for Cancer Research.
Stand Up To Cancer, NIH/National Cancer Institute, Susan G. Komen, Instituto de Salud Carlos III, Prostate Cancer Foundation, Howard Hughes Medical Institute, National Council for Scientific and Technological Development in Brazil

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research

Public Release: 12-Jan-2015
Proceedings of the National Academy of Sciences
Researchers identify new gene mutations linked to colorectal cancer in African-Americans
Case Comprehensive Cancer Center researchers have identified new gene mutations unique to colon cancers in African Americans -- the population with the highest incidence and death rates of any group for this disease. This discovery -- namely, that colorectal cancers appear different on a molecular level in African-Americans -- offers new hope for these patients. With this groundbreaking knowledge, scientists now will seek to develop treatments to target the distinct nature of the disease in African-Americans.
NIH/National Cancer Institute

Contact: Jeannette Spalding
jeannette.spalding@case.edu
216-368-3004
Case Western Reserve University

Public Release: 12-Jan-2015
Cancer
Many cancer survivors have unmet physical and mental needs related to their disease and its treatment
Even decades after being cured, many cancer survivors face physical and mental challenges resulting from their disease and its treatment.

Contact: Evelyn Martinez
sciencenewsroom@wiley.com
Wiley

Public Release: 12-Jan-2015
Cancer
From sexual dysfunction to anxiety, many cancer survivors struggle with post treatment
Even decades after being cured, many cancer survivors face physical and mental challenges resulting from their disease and its treatment. From physical problems such as sexual dysfunction to anxiety about getting cancer again survivors continue to fight long after the actual disease is defeated. That's the conclusion of a study led by University of Central Florida social work professor Mary Ann Burg.

Contact: Zenaida Gonzalez Kotala
zenaida.kotala@ucf.edu
407-823-6120
University of Central Florida

Public Release: 12-Jan-2015
Experimental Hematology
Researchers discover new therapeutic target for treatment of acute myeloid leukemia
A study by the Cancer Science Institute of Singapore at the National University of Singapore has found new interactions between two molecules involved in acute myeloid leukemia (AML), STAT3 and PRL-3, which may offer a new therapeutic target for cancer treatment. The scientists discovered that STAT3, a molecule which has the potential to cause cancer, associates with and regulates the levels of PRL-3, a gene which has been implicated in various types of cancers.

Contact: Kimberley Wang
kimberley.wang@nus.edu.sg
National University of Singapore

Public Release: 12-Jan-2015
Cancer Discovery
Moffitt researchers discover mechanism leading to drug resistance, metastasis in melanoma
Moffitt Cancer Center researchers have discovered a mechanism that leads to resistance to targeted therapy in melanoma patients and are investigating strategies to counteract it. Targeted biological therapy can reduce toxicity and improve outcomes for many cancer patients, when compared to the adverse effects of standard chemotherapeutic drugs. However, patients often develop resistance to these targeted therapies, resulting in more aggressive cells that can spread to other sites or cause regrowth of primary tumors.
National Insitutes of Health, Melanoma and Sarcoma Groningen Foundation, Joanna M. Nicolay Melanoma Foundation.

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 12-Jan-2015
Oncogenesis
Beyond prevention: Sulforaphane may find possible use for cancer therapy
New research has identified one of the key cancer-fighting mechanisms for sulforaphane, and suggests that this much-studied phytochemical found in broccoli and other foods may be able to move beyond cancer prevention and toward therapeutic use for advanced prostate cancer.
National Institutes of Health

Contact: Emily Ho
Emily.ho@oregonstate.edu
541-737-9559
Oregon State University

Public Release: 12-Jan-2015
Journal of Clinical Investigation
CNIO researchers discover 1 of the genetic pieces of bladder cancer
Notch genes protect against bladder cancer, whilst in other tumors they act as oncogenes. Researchers warn that drugs that deactivate Notch in a non-specific manner could increase the risk of developing bladder cancer. Bladder cancer is the fifth most frequent cancer among men in developed countries.

Contact: Nuria Noriega
nnoriega@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)

Public Release: 9-Jan-2015
Nature Communications
Novel breast cancer gene found
Overactivity of the BCL11A gene has been linked to a number of difficult-to-treat breast cancers: triple-negative breast cancer. This discovery will inform the search for new targeted treatments for these hard-to-treat tumors.
Wellcome Trust, Wellcome Trust Sanger Institute, Biotechnology and Biological Sciences Research Council, King's College -- Cambridge, Cancer Research UK, Hutchinson Whampoa Ltd., Medical Research Council

Contact: Mark Thomson
press.officer@sanger.ac.uk
01-223-492-384
Wellcome Trust Sanger Institute

Public Release: 9-Jan-2015
Cancer
Coupling head and neck cancer screening and lung cancer scans could improve survival
Adding head and neck cancer screenings to newly recommended lung cancer screenings would likely improve early detection and survival, according to a multidisciplinary team led by scientists affiliated with the University of Pittsburgh Cancer Institute.
National Institutes of Health

Contact: Allison Hydzik
hydzikam@upmc.edu
412-647-9975
University of Pittsburgh Schools of the Health Sciences

Public Release: 9-Jan-2015
Nature Communications
Bacteria could contribute to development of wound-induced skin cancer
Researchers at King's College London have identified a new mechanism by which skin damage triggers the formation of tumors, which could have important therapeutic implications for patients suffering with chronic ulcers or skin blistering diseases.
Medical Research Council, Wellcome Trust

Contact: Jack Stonebridge
jack.stonebridge@kcl.ac.uk
44-207-848-3238
King's College London

Public Release: 9-Jan-2015
Agent Orange-contaminated airplanes could have affected health of air force reservists
Air Force reservists based in the US who worked after the Vietnam War in C-123 aircraft that sprayed Agent Orange during the war could have experienced adverse health effects from exposure to the herbicide, says a new report from the Institute of Medicine.

Contact: Jennifer Walsh
news@nas.edu
202-334-2138
National Academy of Sciences

Public Release: 9-Jan-2015
International Journal of Radiation Oncology • Biology • Physics
Secondary analysis of RTOG 0247 demonstrates favorable OS rates for rectal cancer patients
Locally advanced rectal cancer patients who receive preoperative radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a four-year overall survival rate of 85 percent and 75 percent, respectively, according to a study published in the Jan. 1, 2015, issue of the International Journal of Radiation Oncology * Biology * Physics, the official scientific journal of the American Society for Radiation Oncology.

Contact: Michelle Kirkwood
press@astro.org
703-286-1600
American Society for Radiation Oncology

Public Release: 9-Jan-2015
Cell Reports
Tumor-blocking role found for cell regulation molecule
Manchester scientists have explored the role of a protein in regulating tumor development and found that it suppresses liver cancer growth in the lab.

Contact: Jamie Brown
Jamie.brown@manchester.ac.uk
44-161-275-8383
University of Manchester

Public Release: 9-Jan-2015
Gut
Mayo researchers find cancer biopsies do not promote cancer spread
A study of more than 2,000 patients by researchers at Mayo Clinic's campus in Jacksonville, Fla., has dispelled the myth that cancer biopsies cause cancer to spread. In the Jan. 9 online issue of Gut, they show that patients who received a biopsy had a better outcome and longer survival than patients who did not have a biopsy.

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-0746
Mayo Clinic

Showing releases 1051-1075 out of 1331.

<< < 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 > >>

  Search News Releases

     

 

EurekAlert!